

# BAY 61-3606

Catalog No: tcsc0235

Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Specifications

#### CAS No:

732983-37-8

### Formula:

 $C_{20}H_{18}N_6O_3$ 

**Pathway:** Protein Tyrosine Kinase/RTK

### **Target:**

Syk

Purity / Grade:

## **Solubility:** 10 mM in DMSO

#### **Observed Molecular Weight:**

390.4

# **Product Description**

BAY 61-3606 is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src.

Copyright 2021 Taiclone Biotech Corp.




IC50 value: 7.5 nM (Ki) [1]

Target: Syk

in vitro: BAY 61-3606 inhibited not only degranulation (IC50 values between 5 and 46 nM) but also lipid mediator and cytokine synthesis in mast cells. BAY 61-3606 was highly efficacious in basophils obtained from healthy human subjects (IC50 = 10 nM) and seems to be at least as potent in basophils obtained from atopic (high serum IgE) subjects (IC50 = 8.1 nM). B cell receptor activation and receptors for Fc portion of IgG signaling in eosinophils and monocytes were also potently suppressed by BAY 61-3606 [1]. We identified BAY61-3606 as an inhibitor of proliferation in colorectal cancer cells expressing mutant forms of K-RAS, but not in isogenic cells expressing wild-type K-RAS. In addition to its anti-proliferative effects in mutant cells, BAY61-3606 exhibited a distinct biological property in wild-type cells in that it conferred sensitivity to inhibition of RAF. In this context, BAY61-3606 acted by inhibiting MAP4K2 (GCK), which normally activates NFk $\beta$  signaling in wild-type cells in response to inhibition of RAF [2].

in vivo: Oral administration of BAY 61-3606 to rats significantly suppressed antigen-induced passive cutaneous anaphylactic reaction, bronchoconstriction, and bronchial edema at 3 mg/kg. Furthermore, BAY 61-3606 attenuated antigen-induced airway inflammation in rats [1].



Copyright 2021 Taiclone Biotech Corp.